News and Analysis
Nature Reviews Drug Discovery 5, 987-988 (December 2006) | doi:10.1038/nrd2204
Fresh from the Pipeline: Panitumumab
Leonard Saltz1, Chris Easley2 & Peter Kirkpatrick3
Top of page
Abstract
In September 2006, panitumumab (Vectibix; Amgen), a fully human antibody against the epidermal growth factor receptor (EGFR), was approved by the FDA for the treatment of patients with EGFR-expressing metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens.
Author affiliations
-
Leonard Saltz is at the Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Email: saltzl@MSKCC.ORG -
Chris Easley is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
ceasley@uk.imshealth.com -
Peter Kirkpatrick is at Nature Reviews Drug Discovery.
Email: p.kirkpatrick@nature.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Medical Oncology IROX as second-line therapy for metastatic colorectal cancerNature Reviews Clinical Oncology News and Views (01 May 2009)
